Author

Ingrid Egeland Christensen

Observed names: Christensen, Ingrid Egeland, I. Egeland Christensen, I.E. Christensen, Ingrid E Christensen, Ingrid E. Christensen

Institution: Diakonhjemmet Hospital

Observed institutions: University of Messina, University of Oslo, Karolinska Institutet, Diakonhjemmet Hospital

ORCID: 0000-0002-8429-8152

Observed ORCID: 0000-0002-8429-8152

OpenAlex ID: A5085955224

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

2022 · Silje Watterdal Syversen, Ingrid Jyssum, et al. · RMD Open · 29

PDF

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

2022 · Kristin H Bjørlykke, Hilde S Ørbo, et al. · The Lancet Rheumatology · 25

PDF

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study

2021 · Ingrid Egeland Christensen, Siri Lillegraven, et al. · Annals of the Rheumatic Diseases · 19

PDF

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

2022 · Ingrid Egeland Christensen, Ingrid Jyssum, et al. · BMC Medicine · 18

PDF

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

2024 · Asia-Sophia Wolf, Kristin H. Bjørlykke, et al. · EBioMedicine · 14

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

2024 · Hilde S Ørbo, Kristin H Bjørlykke, et al. · RMD Open · 7

PDF

Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls

2024 · Ingrid Egeland Christensen, Siri Lillegraven, et al. · Rheumatology Advances in Practice · 4

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study

2024 · Hilde S. Ørbo, Taissa de Matos Kasahara, et al. · The Lancet Regional Health - Europe · 1

AB1353 SAFETY OF UPDATED XBB.1.5 SARS-CoV-2 VACCINE BOOSTERS IN PATIENTS WITH INFLAMMATORY JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPIES

2024 · H.S. Ørbo, I. Jyssum, et al. · Annals of the Rheumatic Diseases · 1

OP0192 SEROLOGICAL RESPONSE AND SAFETY OF A THREE-DOSE SARS-CoV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY

2022 · I. Jyssum, A.T. Tveter, et al. · Annals of the Rheumatic Diseases · 1

PDF

Comment on: Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls: Reply

2025 · Ingrid Egeland Christensen, Siri Lillegraven, et al. · Rheumatology Advances in Practice

PDF

POS0090 CELLULAR AND HUMORAL RESPONSES RESTORED BY UPDATED SARS-CoV-2 VACCINES AND HYBRID IMMUNITY IN PATIENTS ON TNF INHIBITORS: A PROSPECTIVE COHORT STUDY

2024 · H.S. Ørbo, A.S. Wolf, et al. · Annals of the Rheumatic Diseases

AB0070 DURABILITY OF CELLULAR AND HUMORAL IMMUNITY FOLLOWING A FIFTH SARS-CoV-2 VACCINE IN PATIENTS WITH INFLAMMATORY JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPIES

2024 · H.S. Ørbo, I. Jyssum, et al. · Annals of the Rheumatic Diseases

Op0085 Longitudinal T Cell Responses to a Series of Four Sars-cov-2 Vaccine Doses or Covid-19 in Patients on Tnf Inhibitors

2023 · H. Ørbo, A.S.F.M. Wolf, et al. · Annals of the Rheumatic Diseases

PDF

Op0080 Incidence and Clinical Outcome of Covid-19 Related to Post-vaccination Antibody Levels in Patients on Immunosuppressive Therapy: a Prospective Study in the Omicron Era

2023 · H. Ørbo, K.H. Bjørlykke, et al. · Annals of the Rheumatic Diseases

PDF

Pos0537 Safety of Bivalent Sars-cov-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies

2023 · H. Ørbo, I. Jyssum, et al. · Annals of the Rheumatic Diseases

PDF

OP0176 THE PERSISTENCE OF ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-CoV-2 VACCINES IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES USING IMMUNOSUPPRESSIVE THERAPY, COMPARED TO HEALTHY CONTROLS

2022 · I. Egeland Christensen, I. Jyssum, et al. · Annals of the Rheumatic Diseases

PDF

Viral respiratory infections in patients treated with hydroxychloroquine

2021 · Sella A. Provan, Joe Sexton, et al. · Clinical and Experimental Rheumatology

PDF

AB0760 SERIOUS INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS TREATED WITH TNFi: DATA FROM THE NOR-DMARD STUDY.

2020 · I. Egeland Christensen, S. Lillegraven, et al. · Annals of the Rheumatic Diseases

PDF

Works count: 21

Citation count: 119

H-index: 6

I10-index: 5